Browse by Medical Category
The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.
Back to full list of clinical trials
Ongoing clinical trials for Barrett's esophagus: Actively recruiting
Barrett’s Esophagus, esophageal cancer
Discrimination of Barrett’s Metaplasia from Dysplasia with Pathfinder Topographic Genotyping
The aim of the study is to develop a utility to discriminate Barrett’s metaplasia from dysplasia or cancer using Pathfinder topographic genotyping
Basic eligibility criteria:
Patients who underwent biopsy and have a diagnosis of Barrett’s esophagus
William Brugge, MD
Ebubekir Daglilar, MD, CRC; 617-724-0462
Barrett’s esophagus, esophageal cancer
Barrett’s Esophagus Patient Registry (BPR)
The goal of the Barrett’s Esophagus Patient Registry is to help develop more effective targeted screening strategies and treatment options for Barrett’s esophagus and esophageal adenocarcinoma (EAC). We plan to do this by identifying genetic determinants and biomarkers that predict progression of BE to EAC as well as the response to BE therapy.
Patients 18 and older who have been diagnosed with Barrett’s esophagus or esophageal adenocarcinoma based upon standard endoscopic and histologic criteria.
Chin Hur, MD, MPH
Katherine Perzan, CCRC; 617-726-1431
Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention with Metformin
The goal of this study is to find out if metformin, a drug most commonly used to treat type 2 diabetes, can prevent the progression of Barrett’s esophagus to esophageal adenocarcinoma. Metformin has been shown to have potential as a cancer prevention drug in other cancers such as breast and prostate.
Patients 18 and older who have a histologically confirmed diagnosis of Barrett’s esophagus at least 2 cm in length with either no dysplasia or low-grade dysplasia and who have been taking a daily proton pump inhibitor for at least 4 weeks. Patients with a history of high-grade dysplasia or esophageal cancer are not eligible. Patients who have had any kind of ablation or local therapies are also not eligible.
Back to Top